Bristol Myers Squibb (BMY)

Executive Summary

Bristol Myers Squibb (BMY) is a global biopharmaceutical leader with a $122 billion market cap, focused on innovative therapies across oncology, hematology, immunology, and cardiovascular disease. The company's strength lies in its diversified technology platforms, including cell therapy (Breyanzi), immuno-oncology (Opdivo), targeted protein degradation, and radiopharmaceuticals. Recent commercial successes include Opdivo's continued label expansions and the launch of deucravacitinib (Sotyktu) for psoriasis. However, BMS faces headwinds from patent expirations on key drugs like Revlimid and Eliquis, necessitating pipeline progression to offset revenue declines. The company's deep pipeline includes late-stage assets in CAR-T, oral factor XIa inhibitors, and radioconjugates, positioning it for sustainable growth in the mid-term.

Upcoming Catalysts (preview)

• Q3 2026Deucravacitinib (Sotyktu) Phase 3 readout in psoriatic arthritis (POETYK PSO-3)80% success
• Q3 2026Breyanzi (lisocabtagene maraleucel) FDA decision in second-line relapsed/refractory chronic lymphocytic leukemia (CLL)75% success
• Q3 2026Milvexian (factor XIa inhibitor) Phase 3 top-line data for stroke prevention in atrial fibrillation (LIBREXIA-AF)60% success